Clorox (CLX)
(Delayed Data from NYSE)
$161.57 USD
+0.20 (0.12%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $161.52 -0.05 (-0.03%) 7:58 PM ET
2-Buy of 5 2
D Value A Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$161.57 USD
+0.20 (0.12%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $161.52 -0.05 (-0.03%) 7:58 PM ET
2-Buy of 5 2
D Value A Growth B Momentum B VGM
Zacks News
Zacks.com featured highlights include: Clorox, Sprouts Farmers, Eli Lilly, Gold Fields and AngloGold
by Zacks Equity Research
Zacks.com featured highlights include: Clorox, Sprouts Farmers, Eli Lilly, Gold Fields and AngloGold
4 GARP Stocks to Scoop Up for Maximum Returns
by Zacks Equity Research
If you're looking for a profitable portfolio of stocks that will offer the best of value and growth investing, try the growth at a reasonable price or GARP strategy.
Fight Off the Coronavirus Blues With 5 Low-Beta Stocks
by Nilanjan Banerjee
It is an ideal time to invest in low-beta stocks since they might provide a shield against coronavirus-induced market volatility.
Rebalance Your Portfolio to Counter Dilemma Over Recovery
by Nalak Das
At this stage, a combination of aggressive and defensive stocks after filtering with proper selection criteria will be prudent for one's portfolio.
3 Reasons Why Clorox (CLX) Is a Great Growth Stock
by Zacks Equity Research
Clorox (CLX) could produce exceptional returns because of its solid growth attributes.
The Zacks Analyst Blog Highlights: Wayfair, Chegg, Moderna, Quidel and Clorox
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Wayfair, Chegg, Moderna, Quidel and Clorox
International Flavors (IFF) Beats on Q1 Earnings, Scraps View
by Zacks Equity Research
International Flavors (IFF) registers sales and earnings growth in Q1 on broad-based growth in Scent and Taste segments.
PepsiCo Expands Digital Footprint to Meet Consumers' Needs
by Zacks Equity Research
PepsiCo (PEP) launches two websites to cater to the growing online demand for food and beverages.
Is The Clorox (CLX) Outperforming Other Consumer Staples Stocks This Year?
by Zacks Equity Research
Is (CLX) Outperforming Other Consumer Staples Stocks This Year?
An Outstanding Week for Market Amid Record Job Losses: 5 Picks
by Nalak Das
Market's worst is behind us as negative estimates are already factored in valuations.
Zacks.com featured highlights include: Logitech International, MACOM Technology Solutions, Murphy USA, Vertex Pharmaceuticals and The Clorox Company
by Zacks Equity Research
Zacks.com featured highlights include: Logitech International, MACOM Technology Solutions, Murphy USA, Vertex Pharmaceuticals and The Clorox Company
Hain Celestial (HAIN) Up on Q3 Earnings Beat & Raised View
by Zacks Equity Research
Smooth execution of the transformation plan aided Hain Celestial's (HAIN) third-quarter fiscal 2020 performance.
AB InBev (BUD) Posts Q1 Loss on Declines in On-Premise Volume
by Zacks Equity Research
AB InBev's (BUD) first-quarter 2020 results reflect a decline in volume due to the closure of the on-premise channel in most markets, owing to the coronavirus pandemic.
5 Stocks That Look Appealing on Relative Price Strength
by Nilanjan Choudhury
Want to try an out-of-the-box approach to earn handsome returns? Tap these stocks with explosive relative price strength.
Top Ranked Momentum Stocks to Buy for May 7th
by Zacks Equity Research
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, May 7th.
Will Clorox (CLX) Gain on Rising Earnings Estimates?
by Zacks Equity Research
Clorox (CLX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Company News for May 4, 2020
by Zacks Equity Research
Companies in the news are: CLX, CCJ, QSR, BERY
Earnings Data Deluge
by Zacks Equity Research
Earnings Data Deluge.
Clorox (CLX) Q3 Earnings Top, View Up on Coronavirus-Led Demand
by Zacks Equity Research
Strong growth in the disinfecting products and unique product portfolio aided Clorox's (CLX) third-quarter fiscal 2020 results.
Colgate (CL) Beats on Q1 Earnings and Sales, Withdraws View
by Zacks Equity Research
Colgate (CL) delivers strong first-quarter 2020 top and bottom lines, driven by strong volume growth and robust pricing, offset by unfavorable foreign currency.
Quarterly Earnings Beats for Exxon, Clorox, AbbVie & More
by Mark Vickery
Where we find our good news this hour is in quarterly earnings season, where these five big-name companies all outperformed expectations.
Clorox (CLX) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Clorox (CLX) delivered earnings and revenue surprises of 9.88% and 4.03%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
The Zacks Analyst Blog Highlights: Clorox, Sprouts Farmers Market, Hain Celestial, Nomad Foods and Grocery Outlet
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Clorox, Sprouts Farmers Market, Hain Celestial, Nomad Foods and Grocery Outlet
Top Ranked Momentum Stocks to Buy for May 1st
by Zacks Equity Research
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, May 1st.
Molson Coors (TAP) Q1 Earnings Beat Estimates, Sales Down Y/Y
by Zacks Equity Research
Molson Coors (TAP) Q1 results reflect on-premise keg sales returns and reimbursements due to the coronavirus pandemic as well as unfavorable mix.